MedTrace Logo

Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus

NCT05724940 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-02-22

No results posted yet for this study

Summary

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a highly variable presentation and course. It can affect virtually every organ of the body and many symptoms may be observed. Skin, musculoskeletal, hematologic, and serological involvement are most commonly observed. Some patients show predominately hematologic, renal, or central nervous system manifestations.

Studies have reported that juvenile-onset SLE patients tend to have a more aggressive presentation and course, with higher rates of organ involvement and lower life expectancy than adult-onset SLE patients. Late-onset SLE patients tend to have a more insidious onset of disease and tend to have less major organ involvement and more benign disease course. However, they have a poorer prognosis than patients who developed SLE before the age of 50 years, because of the generally higher frequency of comorbid diseases and higher organ damage, due to aging and longer exposure to ''classical'' vascular risk factors.

Aims of the Study:

To compare clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients in our hospital.

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

OTHER

clinical and serological differences among juvenile, adult, and late-onset systemic lupus erythematosus in a cohort of SLE patients

All patients will be subjected to the following: 1. Thorough medical history of the patients 2. Full clinical examination including: 1. General examination and vital signs. 2. Complete rheumatological examination. 3. SLE disease activity index SLEDAI (ref). 4. SLICC( Systemic Lupus International Collaborating Clinics) damage index (ref). 3. Routine investigations (complete blood picture, erythrocyte sedimentation rate and liver functions). 4. Renal investigations: 1. Kidney functions 2. Urine analysis 3. 24 hours protein in urine and/or A/C ratio 4. Renal biopsy if indicated. 5. ANA (Antinuclear Antibodies)test. 6. ANA profile for the most common 19 autoantibodies by immunoblot.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • essam mo aboelfadl, professor · sohag

Eligibility

Min Age
6 Months
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2024-01-01
Completion
2024-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05724940 on ClinicalTrials.gov